{"nctId":"NCT00642642","briefTitle":"Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring","startDateStruct":{"date":"2007-11"},"conditions":["Acne Scarring of the Face"],"count":122,"armGroups":[{"label":"Double blinded active","type":"EXPERIMENTAL","interventionNames":["Biological: Autologous Human Fibroblasts (azficel-T)"]},{"label":"Double blinded placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Autologous Human Fibroblasts (azficel-T)","otherNames":["LAVIV"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female, between 18 years and 65 years of age.\n2. Investigator assessment of the acne scarring on each cheek of moderate to severe.\n3. A history of acne scarring for more than 3 years.\n4. Subject assesses the appearance of both sides of their facial acne scars as dissatisfied or very dissatisfied with appearance.\n\nExclusion Criteria:\n\n1. Significant active acne.\n2. Use of oral antibiotic or retinoid active acne therapy within one year of enrollment.\n3. Presence of hypertrophic scars on the cheeks.\n4. More than 20% of treatment area comprised of ice pick scars or sinus tracts\n5. Treatment area per cheek is less than 9 cm x cm\n6. Unilateral or unbalanced acne scar distribution.\n7. Physical attributes which prevent the assessment or treatment of the acne scars.\n8. Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study.\n9. Previous treatment with Isolagen TherapyTM.\n10. Use of Isotretinoin within one year of enrollment into study.\n11. Use of permanent or semi-permanent dermal fillers in the treatment areas within defined time frames.\n12. Disorders or drugs that increase bleeding or clotting.\n13. Pregnant or lactating women or women trying to become pregnant during the study.\n14. Excessive exposure to sun.\n15. Smoking more than Â½ pack of cigarettes per day.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Evaluator Live Acne Scarring Assessment Responders","description":"Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"PRIMARY","title":"Subject Live Acne Scarring Assessment Responders","description":"Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluator Live Acne Scarring Assessment Responders","description":"Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject Live Acne Scarring Assessment Responders","description":"Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":122},"commonTop":["Erythema","Swelling"]}}}